

Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/R1CEA39150D1EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: R1CEA39150D1EN

Abstracts

The 7 major renal cell carcinoma markets reached a value of US\$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 7.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The renal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Renal cell carcinoma refers to kidney cancer that develops in the lining of the proximal convoluted tubule, a section of the tiny tubes in the kidney that carry primary urine. This condition usually doesn't have any symptoms in its early stages. However, in time, individuals suffering from the ailment may experience blood in the urine, which may appear pink, red, or cola-colored, back pain, loss of appetite, unexplained weight loss, tiredness, fever, etc. The other common indications associated with this disease include increased abdominal mass, malaise, sleep disturbances, night sweats, high blood calcium levels, anemia, etc. The diagnosis of renal cell carcinoma is based on the patient's symptoms, medical history, and physical exam. A range of biochemical tests using urine and/or blood samples are also performed to provide adequate quantitative analysis of any differences in electrolytes. The other diagnostic procedures for detecting this disease include ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) scans, etc.

The increasing cases of inherited genetic disorders, which cause DNA abnormalities and gene mutations, are primarily driving the renal cell carcinoma market. In addition to this, the rising prevalence of various risk factors, including advancing age, smoking, obesity, hypertension, certain medications, etc., is also bolstering the market growth. Furthermore, the inflating utilization of intravenous pyelograms to detect the presence of

an unhealthy renal mass in the urinary tract is creating a positive outlook for the market. This minimally invasive method involves the injection of a contrasting dye into the patient's arm, which, over time, reaches the bladder and kidneys to provide a detailed image of the surrounding area. Additionally, the rising usage of nephron-sparing partial nephrectomy, since it allows the removal of a cancerous tumor or diseased tissue without damaging the healthy kidney cells, is acting as another significant growth-inducing factor. Moreover, several technological advancements in the field of percutaneous ablation therapies, including the launch of radiofrequency ablation and cryoablation, are improving treatment outcomes in patients while minimizing unwanted effects. This, in turn, is expected to drive the renal cell carcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the renal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for renal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the renal cell carcinoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the renal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the renal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current renal cell carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the renal cell carcinoma market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the renal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the renal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with renal cell carcinoma across the seven major markets?

What is the size of the renal cell carcinoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of renal cell carcinoma?

What will be the growth rate of patients across the seven major markets?

Renal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for renal cell carcinoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the renal cell carcinoma market?

What are the key regulatory events related to the renal cell carcinoma market?

What is the structure of clinical trial landscape by status related to the renal cell carcinoma market?

What is the structure of clinical trial landscape by phase related to the renal cell carcinoma market?

What is the structure of clinical trial landscape by route of administration related to the renal cell carcinoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 RENAL CELL CARCINOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 RENAL CELL CARCINOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 RENAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 RENAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 RENAL CELL CARCINOMA - UNMET NEEDS

10 RENAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT

11 RENAL CELL CARCINOMA - MARKETED PRODUCTS

- 11.1 List of Renal Cell Carcinoma Marketed Drugs Across the Top 7 Markets

11.1.1 Fotivda (Tivozanib) - AVEO Oncology/Kyowa Kirin

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

11.1.2 Proleukin (Aldesleukin) - Clinigen/Novartis

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

11.1.3 Sutent (Sunitinib) - Pfizer

- 11.1.3.1 Drug Overview
- 11.1.3.2 Mechanism of Action
- 11.1.3.3 Regulatory Status
- 11.1.3.4 Clinical Trial Results
- 11.1.3.5 Sales Across Major Markets

11.1.4 Inlyta (Axitinib) - Pfizer

- 11.1.4.1 Drug Overview
- 11.1.4.2 Mechanism of Action
- 11.1.4.3 Regulatory Status
- 11.1.4.4 Clinical Trial Results
- 11.1.4.5 Sales Across Major Markets

11.1.5 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co

- 11.1.5.1 Drug Overview
- 11.1.5.2 Mechanism of Action
- 11.1.5.3 Regulatory Status
- 11.1.5.4 Clinical Trial Results
- 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 RENAL CELL CARCINOMA - PIPELINE DRUGS

12.1 List of Renal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets

12.1.1 Pexastimogene Devacirepvec - SillaJen Biotherapeutics

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 Batiraxcept - Aravive
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 CTX130 - CRISPR Therapeutics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 XmAb819 - Xencor
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 CMN-001 - Colmmune
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. RENAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. RENAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 RENAL CELL CARCINOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Renal Cell Carcinoma - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Renal Cell Carcinoma - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Renal Cell Carcinoma - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Renal Cell Carcinoma - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Renal Cell Carcinoma - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Renal Cell Carcinoma - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Renal Cell Carcinoma - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Renal Cell Carcinoma - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Renal Cell Carcinoma - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Renal Cell Carcinoma - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Renal Cell Carcinoma - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Renal Cell Carcinoma - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Renal Cell Carcinoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Renal Cell Carcinoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Renal Cell Carcinoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Renal Cell Carcinoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Renal Cell Carcinoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Renal Cell Carcinoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Renal Cell Carcinoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Renal Cell Carcinoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Renal Cell Carcinoma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Renal Cell Carcinoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Renal Cell Carcinoma - Access and Reimbursement Overview

16 RENAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 RENAL CELL CARCINOMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 RENAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R1CEA39150D1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R1CEA39150D1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

